Heterobivalent ligands target cell-surface receptor combinations in vivo.
about
Nanoparticle ligand presentation for targeting solid tumorsUniversal Molecular Scaffold for Facile Construction of Multivalent and Multimodal Imaging ProbesDesign and applications of bispecific heterodimers: molecular imaging and beyondCancer targeted therapeutics: From molecules to drug delivery vehicles.Peptides and peptidomimetics as immunomodulators.An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy.A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the PancreasTrigonal scaffolds for multivalent targeting of melanocortin receptors.Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptor.Imaging and Force Recognition of Single Molecular Behaviors Using Atomic Force Microscopy.Guiding principles in the design of ligand-targeted nanomedicines.Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells.Heterobivalent agents targeting PSMA and integrin-αvβ3.Cell-surface marker discovery for lung cancer.
P2860
Q27009522-35E2F4D7-8507-4275-B94E-C3CD611FE935Q28834080-EB0E21A8-828F-405A-B1DD-29C83F4EDA6BQ33732587-A0B6CC89-45A9-4101-96B0-FF17BFA277CFQ33887986-5393CD4B-0B93-4C1F-B63F-AAEA3BB45B29Q34359984-3C48206E-2C90-44F3-84A9-79CE65A801EDQ34517465-F76BF1A3-512F-4FAA-ABCA-2698B7FD4C4DQ34550143-43FEDF00-FC55-4AD5-87AD-19685EEC5FC2Q35781719-C3E9C799-75CB-485C-B033-424042DD3ED4Q36395175-7093A920-B361-4E7E-B04D-AE0E02E69CA3Q36658378-65C7AEC0-2D22-4EA2-9BE6-F7C7A893D695Q37075319-29BC7B7B-D196-4263-B7F3-5F2BB1C9E46AQ37254458-C44B0494-BF03-4D2E-8923-72EBCD564F59Q37632726-83DDF3E3-8339-4C06-BB82-61A96363F56DQ38189490-4B151EE0-27CD-4F56-B94D-71F753334BAFQ38753981-C30897C2-4511-4064-8545-09CAB664F3B5Q39211934-17DFD73E-1910-4EDF-8F63-9E06A9C5EF44Q42737891-C4B73A41-25C6-44B5-A95C-8668D23BF915Q42751344-D937FA85-38D2-445C-918F-139DC1B7F11EQ49325404-1F935C43-33B4-459F-B98B-4CEC6DC39BCE
P2860
Heterobivalent ligands target cell-surface receptor combinations in vivo.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@ast
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@en
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@nl
type
label
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@ast
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@en
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@nl
prefLabel
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@ast
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@en
Heterobivalent ligands target cell-surface receptor combinations in vivo.
@nl
P2093
P2860
P356
P1476
Heterobivalent ligands target cell-surface receptor combinations in vivo
@en
P2093
David L Morse
Eugene A Mash
Josef Vagner
Michael R Caplan
Ronald M Lynch
Victor J Hruby
P2860
P304
21295-21300
P356
10.1073/PNAS.1211762109
P407
P577
2012-12-10T00:00:00Z